#United Kingdom #Oxford #Brainomix #AI Imaging #Stroke Treatment

Brainomix Enhances Stroke Treatment Decisions through AI at ESOC 2025

In a significant advance for stroke treatment, Brainomix, a leader in AI-powered imaging solutions, presented groundbreaking findings at the European Stroke Organisation Conference (ESOC) in Helsinki. Recent studies highlighted the impact of their Brainomix 360 Stroke software, which has now been associated with a notable increase in mechanical thrombectomy rates among various healthcare centers.

According to Gary Ford, Professor of Stroke Medicine at Oxford University, the latest findings come from the largest prospective evaluation of stroke imaging AI. The results reveal that utilizing Brainomix 360 Stroke led to a stunning 104% increase in mechanical thrombectomy rates at primary stroke centers, along with a 73% increase at comprehensive stroke centers. This improvement signifies a network-wide advantage, enabling more patients to access this critical procedure that can significantly enhance their recovery.

Further notable insights were shared by Dr. Albert Yoo from the Texas Stroke Institute. In collaboration with the TESLA Trial team, he analyzed data to assess the ischemic core volume and hypoattenuation during the initial scans for nearly 300 patients suffering from large vessel occlusions. His findings underscored the importance of these factors in determining the suitability of patients for endovascular treatment, reinforcing the necessity for advanced imaging methods in stroke care.

Building on these developments, Brainomix also introduced innovative biomarkers in a new study conducted with leading experts from the Mayo Clinic and West Virginia University. This research focused on brain frailty as a crucial predictor for functional outcomes in patients undergoing mechanical thrombectomy. George Harston, Chief Medical Innovation Officer at Brainomix, emphasized the relevance of their next-generation biomarkers in assessing brain frailty, marking it as a valuable criterion for treatment eligibility.

Additionally, Brainomix supported several studies at ESOC, presenting further validation of their imaging software's accuracy. For instance, Dr. Amelia Adcock reported findings comparing Brainomix 360 Stroke with Viz.ai, demonstrating superior sensitivity in detecting certain occlusions. Moreover, a collaborative study with Boston Medical Center highlighted the effectiveness of the automated hemorrhage detection tool, achieving a remarkable 93% sensitivity in identifying intracerebral hemorrhage cases. This showcases how Brainomix 360 Stroke efficiently assists clinicians in triaging and notifying of critical cases.

Another valuable study highlighted the utility of CT Perfusion processed with Brainomix 360 Stroke, effectively distinguishing stroke mimics from genuine strokes—a pivotal development that could streamline patient care and reduce inappropriate treatments.

As a private company deriving its roots from Oxford University, Brainomix has developed a robust presence in the AI healthcare landscape, operating in over 20 countries. Their award-winning imaging solutions have been adopted in numerous hospitals worldwide, enhancing patient care significantly. The Brainomix 360 Stroke platform stands at the forefront, empowering healthcare providers to make data-driven treatment decisions that improve patient outcomes.

For those interested in learning more about Brainomix and their revolutionary technology, visit www.brainomix.com and follow their updates on social media platforms. The future of stroke treatment is illuminated by continuous innovation and research from Brainomix, promising a brighter path for patients battling strokes across the globe.